ABSTRACT We sought to determine if verapamil induces frequency-dependent prolongation of atrioventricular nodal conduction in 10 consecutive patients studied in the electrophysiology laboratory. We used a maintenance infusion of verapamil designed to produce plasma concentrations of verapamil in the "therapeutic" range and that did not alter heart rate or blood pressure significantly. Frequency-dependent prolongation of atrioventricular nodal conduction (AH interval) was demonstrated in all 10 patients (p < .001), and no change in HV conduction time with decreasing cycle length was noted in any patient while receiving verapamil. Two patterns of use-dependent response were seen. In four patients frequency-dependent prolongation of the A(AH) interval [I\(AH) = AHverapamil -AHcontrol at a given cycle length] was seen with each decrement in pacing cycle length. In six patients frequencydependent prolongation of the A(AH) interval was not manifest until the fifth to eighth pacing cycle length tested. There was no association between the pattern observed and the initial heart rate or AH interval. After an abrupt change in pacing cycle length, the kinetics of A(AH) interval prolongation were rapid; equilibrium was achieved by five to eight pulses in all patients. There was no correlation between the magnitude of prolongation of the AH interval noted at a particular cycle length and the concentration of verapamil during the maintenance infusion. These results indicate that verapamil causes use-dependent prolongation of atrioventricular nodal conduction in man. Circulation 72, No. 2, 344-352, 1985. A DESIRABLE GOAL of antiarrhythmic drug therapy is to terminate or suppress tachycardia without affecting impulse initiation or propagation at physiologic heart rates." 2 Ideally, a drug used to treat reentrant tachycardia will demonstrate maximal effects on conduction and refractoriness during tachycardia, but will have minimal effects at slower heart rates after its termination. The extent of a drug's effects on conduction velocity can be inferred from its effects on phase 0 maximum upstroke velocity (Vmax) of the action potential. 
A DESIRABLE GOAL of antiarrhythmic drug therapy is to terminate or suppress tachycardia without affecting impulse initiation or propagation at physiologic heart rates." 2 Ideally, a drug used to treat reentrant tachycardia will demonstrate maximal effects on conduction and refractoriness during tachycardia, but will have minimal effects at slower heart rates after its termination. The extent of a drug's effects on conduction velocity can be inferred from its effects on phase 0 maximum upstroke velocity (Vmax) of the action potential. 3 In 1957, Johnson and McKinnon4 showed that quinidine decreased Vmax progressively as the driving rate was increased. Observations similar to this have been made with other local anesthetic types of antiarrhythmic drugs in nerve and cardiac muscle. ", 2 Subse-quent studies in nerve and cardiac muscle have characterized the use-or frequency-dependent action of local anesthetic agents, leading to the evolution of the modulated receptor hypothesis.5 6 Experiments in vitro have demonstrated use-dependent block for a variety of sodium channel-blocking agents, including disopyramide, flecainide, mexiletine, and lidocaine.7 10 Recently, preliminary reports have appeared describing frequency-dependent prolongation of conduction time in the human heart with procainamide, amiodarone, lidocaine, and mexiletine. " 12 Use-dependent block has also been demonstrated for calcium-channel blockers in vitro. Wit and Crane- field`3 studied the effects of verapamil on isolated rabbit atrioventricular nodes and were able to demonstrate frequency-dependent prolongation of atrioventricular nodal conduction. In 1975, while studying the effect of verapamil on cat papillary muscle, Bayer et al. '4 11 were also able to infer that the drug caused frequencydependent blockade of the slow inward current. Later, Ehara and Kaufman'6 and McDonald et al. ' 7 directly demonstrated frequency-dependent block of the calcium current with verapamil and its cogener, methoxy-verapamil. Excitation and, as a result, conduction in the atrioventricular node, are dependent on the slow inward (calcium) current. 18 Extrapolation of these findings in vitro to man would predict that the effect of verapamil on atrioventricular conduction should be frequency dependent. Demonstration of this action would represent a significant advance in our understanding of the relevance of these findings in vitro to man.
Methods
The study group consisted of 10 consecutive adult patients referred for electrophysiologic evaluation of symptomatic or suspected cardiac arrhythmias. Patients were excluded from this study if they demonstrated manifest preexcitation on the electrocardiogram, atrioventricular block on Holter or electrocardiographic monitoring, an ejection fraction less than 30% as determined by radionuclide angiography, two-dimensional echocardiography, or cardiac catheterization, or if they had symptomatic congestive heart failure. Patients taking calcium antagonists (nifedipine, diltiazem, verapamil), fl-blockers, or digoxin were also excluded from this study. All cardioactive medications were withheld for at least five half-lives before the study. Informed consent was obtained from all patients.
Electrophysiologic study protocol. The studies were performed in nonsedated, fasting patients. Three multipolar catheters were introduced percutaneously and positioned in the heart under fluoroscopic guidance in the right atrial appendage, across the tricuspid valve to record a His bundle potential, and in the right ventricular apex in each patient. Stimulation was performed with a custom-designed, programmable stimulator with an optically isolated current source producing 2 msec pulses at twice diastolic threshold. Bipolar intracardiac electrograms were recorded with five surface electrocardiographic leads (I, II, III, VI, and V6) and were displayed on an oscilloscope. Graphic records were obtained on-line with a multichannel ink-jet recorder (Siemens Mingograph) at 200 mm/sec. A 10 msec time code was generated with the data during all recordings.
The following routine intracardiac electrophysiologic studies were performed on all patients: (1) Incremental atrial pacing was performed beginning at rates just above the sinus rate to the point at which atrioventricular block occurred. (2) Right atrial refractory period was determined by the extrastimulus technique at a driven cycle length of 600 msec. In each of six patients, atrial pacing was performed for 2 min at a driven cycle length of 50 to 100 msec shorter than the patient's spontaneous cycle length and was then suddenly decreased by 100 to 150 msec. Continuous recordings were obtained during pacing. Each patient then underwent incremental atrial pacing for 1 min at each cycle length, starting at cycle lengths just below the sinus cycle length and decreasing stepwise (25 msec steps) until atrioventricular block occurred. Graphic records were obtained during the last 10 sec at each pacing cycle length for data analysis.
All patients then received 10 mg of verapamil (Isoptin, Knoll Pharmaceutical, Whippany, NJ) in 4 ml of saline administered intravenously over 2 min. Blood pressure was monitored by an external continuous monitor (Infrasonde model D4000), and rhythm was monitored continuously during the verapamil infusion. Each patient then received a rapid loading infusion of verapamil, 0.375 mg/min for 30 min, followed by a maintenance infusion at 0.125 mg/min via Plasma verapamil concentration. The verapamil level was determined 2 min after the beginning of the maintenance infusion (0.125 mg/min). The levels ranged from 37 to 125 ng/ml (mean + SD, 85 + 35 ng/ml).
Hemodynamics. Analysis of measurements of blood pressure showed a 12% decrease in mean systolic blood pressure at 2 min during the bolus phase of drug administration, which was a significant decrease (p < .05). There was no significant change in mean diastolic blood pressure at 2 min (p > .05). Mean heart rate (82 beats/min) increased significantly at 2 min (90 beats/min, p < .05). There was no significant change in mean heart rate, systolic pressure, or diastolic pressure during the loading and maintenance phases of the verapamil infusion (p < .05). These results are presented in figure 1. Kinetics. To determine the kinetics of change in AH interval during incremental pacing, pacing at a cycle length of 500 or 750 msec for 2 min was followed by an abrupt 100 to 150 msec cycle length decrease, and the number of beats needed for the AH interval to reach In six patients (Nos. 1, 3, 4, 6, 9, and 10) there was no 60 B change in the A(AH) interval for the initial four to seven cycle lengths tested; however, at subsequent 50-""""""|||""||"""""""|"""" ient in whom the effective and functional reFrequency dependence of HV conduction time. Since periods of the atrioventricular node could be verapamil has been shown to decrease phase 0 Vmax in red, there was an increase in these parameters polarized ventricular muscle cells, we also examined e infusion of verapamil of approximately 30% the effects of verapamil on conduction time of the HV 0% to 60%). The minimum cycle length at interval. There was no change in the mean HV conduc-1 atrioventricular conduction was present intion time as the cycle length was decreased at control by 100 to 175 msec after infusion of drug.
or during the infusion of verapamil. This is illustrated ,ncy dependence of atrioventricular nodal conducin figure 5 , B, for the six patients in which atrial pacing .In the baseline electrophysiology study, as was begun at a cycle length of 800 msec. correlation between the verapamil level during the maintenance infusion and the A(AH) intervals observed at cycle lengths of 800 msec (n = 6, r = .7, p > .05), 600 msec (n = 5, r = -.02, p > .05), 500 msec (n =4, r = -.8, p > .05), and 400 msec (n 4, r = -.7, p > .05).
Discussion
The most important finding of this study is the demonstration of verapamil's frequency-dependent prolongation of AH conduction time in man. After an abrupt change in atrial pacing cycle length, the AH interval rapidly reached a new equilibrium value within 8 beats. On the other hand, verapamil had no effect on the HV interval at any pacing cycle length tested. We could not establish any correlation between verapamil concentration and the magnitude of the /(AH) interval at any cycle length tested.
One of the most intriguing findings to emerge from studies of use-or frequency-dependent block of local anesthetic type antiarrhythmic drugs has been that these drugs preferentially slow conduction during tachycardia, but have relatively little effect on conduction at normal heart rates. These studies have also led to the evolution of the modulated receptor hypothesis that states that local anesthetic types of antiarrhythmic drugs diffuse to a binding site in the aqueous pore of the ionic channel through either an aqueous (hydrophilic) or membrane (hydrophobic) pathway.5 6 Since most antiarrhythmic agents have pKaS in the 7 to 10 348 range, they exist as a combination of the neutral and the charged forms of the drug. Receptor affinity or access of drugs to the binding site is believed to vary with the state of the channel.) 6. 22 For example, with depolarization of a Purkinje fiber, the majority of the sodium channels will be transiently shifted to the open or activated state. In this state, both charged and uncharged forms of the drug can access the sodium channel through the hydrophilic pathway from the inside of the cell and the uncharged form can access the channel through the hydrophobic pathway in the membrane. During the plateau phase of repolarization, the majority of sodium channels are in the inactivated state, and now access to the sodium-channel binding site is restricted to the uncharged form of the drug via the membrane (hydrophobic) path. Association of drug with the ionic channel occurs predominantly during the upstroke and plateau phase of the action potential, while dissociation occurs predominantly during diastole. 1 2, 22 When the drug is bound to its receptor site in the channel, that channel can no longer conduct. Thus, as the driving rate of a preparation is increased, the rest (diastolic) interval becomes shortened, and there is less time for the drug to dissociate from the channels and to completely recover from block. Over the next nine CLs, the AH interval progressively increased in magnitude. A similar pattern was seen in patient 6 (C), despite the small baseline increment in the AH interval during the infusion of verapamil. The calcium-dependent slow inward current plays a major role in transmission of impulses through the atrioventricular node. Studies performed in the 1970s demonstrated that the calcium current is primarily responsible for the action potential upstroke in N and NH cells of the atrioventricular node. 18 Verapamil is known to depress calcium current in voltage-clamped preparations of atrioventricular node obtained from mammalian myocardium.27 Since propagation velocity in the atrioventricular node is dependent on the underlying calcium current as well as passive membrane properties, a drug-induced decrease in ionic current should be reflected in a prolongation of atrioventricular nodal conduction time.
Unfortunately, there is a scarcity of clinical evidence indicating that use-dependent blockade may occur in humans. Evidence for its presence could be inferred from the observation of frequency-dependent changes in propagation velocity or conduction time. Recently, preliminary observations have suggested that type I antiarrhythmic drugs will cause cycle length-dependent prolongation of the HV interval or QRS duration. 12 However, there have been no studies in which the possibility of use-dependent blockade by calcium-(slow-current) blocking drugs has been examined in man.
In our study, frequency-dependent prolongation of the AH interval was demonstrated in each patient. Two patterns of prolongation of the AH interval were noted. One pattern showed a constant A(AH) interval for the first four to seven pacing cycle lengths tested, followed by progressively increasing A(AH) intervals at the remaining pacing cycle lengths. The second pattern demonstrated a nonlinear increase in A(AH) interval that was noted by the second cycle length tested. There was no correlation between the pattern of use dependence seen and the baseline heart rate or AH interval. Furthermore, there was no correlation between hemodynamic response to the infusion of verapamil and the pattern of frequency dependence observed. There are several other factors that would be expected to modulate the magnitude and pattern of frequency-dependent prolongation of the AH interval. Cellular phenomena, such as changes in diastolic membrane potential, may cause different degrees of tonic block.2' 22 Catecholamines have been shown to augment the calcium-channel current, and changing catecholamine levels could modulate the degree of prolongation of the AH interval seen with rapid atrial pacing.28 Finally, atrioventricular nodal conduction reflects a wide spectrum of atrioventricular nodal physiology, and interindividual differences in baseline properties could contribute to the different responses we observed with incremental atrial pacing. 29 The kinetics of equilibration of the AH interval with abrupt changes in atrial pacing cycle length in man were studied to compare our observations on conduction time in vivo with observations on 37' 40 Thus, these data suggest that the frequency-or rate-dependent effects demonstrated in this study are of sufficient magnitude to be of therapeutic significance in the termination of paroxysmal supraventricular tachycardia.
In conclusion, the results of this study demonstrate use-dependent blockade of atrioventricular nodal conduction with verapamil in man. The kinetics of block are rapid and were achieved in five to eight pulses. There was no evidence of use-dependent prolongation of His-Purkinje conduction (HV interval). The degree of use dependence observed in this study did not correlate with the verapamil concentration.
